

## 40 C.F.R. § 700.43

---

### Definitions applicable to this subpart.

---

Definitions in section 3 of the Act (15 U.S.C. 2602), as well as definitions contained in §§ 704.3, 720.3, 723.175(b), 725.3, and 790.3 of this chapter, apply to this subpart unless otherwise specified in this section. In addition, the following definitions apply:

*Consolidated microbial commercial activity notice* or *consolidated MCAN* means any MCAN submitted to EPA that covers more than one microorganism (each being assigned a separate MCAN number by EPA) as a result of a prenotice agreement with EPA.

*Consolidated premanufacture notice* or *consolidated PMN* means any PMN submitted to EPA that covers more than one chemical substance (each being assigned a separate PMN number by EPA) as a result of a prenotice agreement with EPA (See 48 FR 21734).

*Consortium* means an association of manufacturers and/or processors who have made an agreement to jointly split the cost of applicable fees.

*Enforceable consent agreement* means a consent agreement used by EPA to accomplish testing where a consensus exists among EPA and interested parties (as identified in § 790.22(b)(2)) concerning the need for and scope of testing under section 4 of the Act.

*EPA-initiated risk evaluation* means any risk evaluation conducted pursuant to section 6(b)(4)(C)(i) of the Act.

*Exemption notice* means any notice submitted to EPA under § 723.175 of this chapter.

*Final product* means a new chemical substance (as “new chemical substance” is defined in § 720.3 of this chapter) that is manufactured by a person for distribution in commerce, or for use by the person other than as an intermediate.

This document is only available to subscribers. Please [log in](#) or [purchase access](#).

[Purchase Login](#)